ARTL
ARTELO BIOSCIENCES, INC.
$1.42
+4.41%
$3.2M
No data for this timeframe.
Vol
Market Cap$3.2M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$42.4K
Inst. Activity2 buys / 0 sells
Reddit Sentiment54° Neutral
SEC Reports11
Press Releases4
Recent Activity
May 18, 2026
SEC
Artelo Biosciences terminated its At-The-Market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 20
424B5 — Impact 4/10
May 15, 2026
SEC
Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty, which had allowed up to $6.5M in
8-K — Impact 3/10
May 14, 2026
SEC
Artelo Biosciences filed Amendment No. 1 to its S-3 shelf registration statement solely to add a form of indenture (Exhi
S-3/A — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
20,669 shares ($25.2K)
Inst.
BANK OF AMERICA CORP — ADD
17 shares ($21.00)
May 19, 2026
earnings_calendar
ARTL Q1 2026 Earnings Scheduled — 2026-05-19
Apr 28, 2026
Press
Artelo Biosciences announced a strategic partnership with AI company ScienceMachine to accelerate development of its FAB
Impact 3/10
Apr 20, 2026
Press
Artelo Biosciences announced the publication of a peer-reviewed article supporting FABP5 inhibition as a novel, non-opio
Impact 7/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 19, 2025 | Maxim Group | DOWNGRADE | Buy → Hold |
| Sep 8, 2025 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Aug 26, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Aug 18, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Aug 6, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-9.84 ▼ -343.2% | $-9.84 — $-9.84 | 74% YoY | 1 |
| Next FY | $-5.28 ▼ -203.4% | $-5.28 — $-5.28 | 46% YoY | 1 |
Latest Reports
NEUTRAL
424B5
4/10
Artelo Biosciences terminated its At-The-Market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 20
May 18, 2026
NEUTRAL
8-K
3/10
Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty, which had allowed up to $6.5M in
May 15, 2026
NEUTRAL
Press
3/10
Artelo Biosciences announced a strategic partnership with AI company ScienceMachine to accelerate development of its FAB
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP | $25.2K | NEW |
| VANGUARD GROUP INC | $17.1K | NEW |
| BANK OF AMERICA CORP | $21.00 | ADD |
Reddit Sentiment
54°▲
Neutral
Bearish
Neutral
Bullish
3 institutional holders with $42.4K total value (34,714 shares) as of 2025-Q4. Top holders: TWO, VANGUARD, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | 20,669 | $25.2K | 59.5% | NEW |
| 2 | VANGUARD GROUP INC | 14,028 | $17.1K | 40.4% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 17 | $21.00 | 0.0% | ADD +54.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 20,669 | — | $25.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 11 | 17 | +54.5% | $21.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 14,028 | — | $64.4K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 4 | 1,100 | +27400.0% | $5.0K | 2025-Q3 |
| UBS Group AG | DOUBLED | 89 | 209 | +134.8% | $959.00 | 2025-Q3 |
| FMR LLC | DOUBLED | 1 | 30 | +2900.0% | $138.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 5 | 11 | +120.0% | $50.00 | 2025-Q3 |
| UBS Group AG | EXIT | 12,772 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 22,706 | — | $19.9K | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
11 SEC filing reports analyzed. Sentiment: 0 bullish, 6 bearish, 1 mixed, 4 neutral. Avg impact: 5.5/10.
NEUTRAL
424B5
4/10
Artelo Biosciences terminated its At-The-Market (ATM) equity offering agreement with R.F. Lafferty,
May 18, 2026
NEUTRAL
8-K
3/10
Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty, which had all
May 15, 2026
BEARISH
S-3/A
6/10
Artelo Biosciences filed Amendment No. 1 to its S-3 shelf registration statement solely to add a for
May 14, 2026
BEARISH
S-1
7/10
Artelo Biosciences is conducting a best-efforts public offering to register up to 9.8 million shares
Apr 7, 2026
NEUTRAL
8-K
4/10
Artelo Biosciences regained compliance with Nasdaq's stockholders' equity and annual meeting listing
Apr 7, 2026
BEARISH
EFFECT
7/10
Artelo Biosciences' IPO registration has become effective, allowing the company to begin selling up
Mar 31, 2026
BEARISH
S-1
7/10
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics targeting l
Mar 24, 2026
BEARISH
S-1/A
6/10
Artelo Biosciences is conducting a best-efforts public offering to raise up to $12 million through t
Mar 24, 2026
MIXED
S-1/A
6/10
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics targeting l
Mar 23, 2026
BEARISH
S-1
7/10
Arteo Biosciences (ARTL) is conducting a best-efforts public offering of up to 1.64 million shares a
Mar 20, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K reports entry int
Mar 18, 2026
NEUTRAL
3/10
Artelo Biosciences announced a strategic partnership with AI company ScienceMachine to accelerate de
Apr 28, 2026
BULLISH
7/10
Artelo Biosciences announced the publication of a peer-reviewed article supporting FABP5 inhibition
Apr 20, 2026
BEARISH
6/10
Artelo Biosciences closed a private placement offering of 3,188,407 shares (or pre-funded warrants)
Mar 30, 2026
NEUTRAL
5/10
Artelo Biosciences announced a private placement of 3,188,407 shares (or pre-funded warrants) and ac
Mar 27, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-9.84 | $-9.84 | $-9.84 | 73.8% | -343.2% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-5.28 | $-5.28 | $-5.28 | 46.3% | -203.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
4 analyst firms have rated this stock: 1 upgrades, 3 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 19, 2025 | Maxim Group | DOWNGRADE | Buy | Hold |
| Sep 8, 2025 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Aug 26, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Aug 18, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Aug 6, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Aug 4, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jul 8, 2025 | D. Boral Capital | UPGRADE | Hold | Buy |
| Jun 11, 2025 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Jun 6, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 28, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 2, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 3, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 27, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 14, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 9, 2024 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 9, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 3, 2023 | Ladenburg Thalmann | REITERATE | — | Buy |
| Feb 3, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Aug 12, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
54°
Neutral
Bearish
Neutral
Bullish
8 mentions
1 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 29, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 29, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 3 | 57° Neutral | 1 | 0 | 3 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 21, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 21, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$ARTL +208% — glaucoma study expansion into $16B market
▲ 1
💬 0
⚡ 0.5
Finally had a green day using the ORB strategy
▲ 1
💬 1
⚡ 0.5
$ARTL +208% — glaucoma study expansion into $16B market
▲ 1
💬 0
⚡ 0.5
Stock Pulse Weekly Recap — Mar 24–28, 2026
▲ 1
💬 1
⚡ 0.5
$ARTL +208% — glaucoma study expansion into $16B market
▲ 1
💬 1
⚡ 0.5
May 19, 2026
earnings_calendar
ARTL Q1 2026 Earnings Scheduled — 2026-05-19
May 13, 2026
earnings_calendar
ARTL Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
ARTL Q1 2026 Earnings Scheduled — 2026-05-11
Apr 28, 2026
contract
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
<p align="justify">SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Artelo Biosciences, Inc. (Nasdaq: ARTL),</strong> a clinical-sta
Apr 21, 2026
short_interest
FTD: ARTL — 783,554 shares ($3.5M) failed to deliver
Settlement: 20260421, Price: $4.53, FTD Value: $3,549,499.62, ARTELO BIOSCIENCES INC COM NEW
Apr 20, 2026
fda
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
<p align="center"><em>Demonstrates ART26.12’s Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This
Apr 7, 2026
other
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a) <pre>Nasdaq confirms Company has regained compliance with Li
Mar 31, 2026
short_interest
FTD: ARTL — 134,529 shares ($1.2M) failed to deliver
Settlement: 20260331, Price: $8.73, FTD Value: $1,174,438.17, ARTELO BIOSCIENCES INC COM NEW
Mar 30, 2026
offering
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
<p align="justify">SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.<strong> (Nasdaq: ARTL)</strong> today announced
Mar 30, 2026
short_interest
FTD: ARTL — 343,830 shares ($3.6M) failed to deliver
Settlement: 20260330, Price: $10.54, FTD Value: $3,623,968.2, ARTELO BIOSCIENCES INC COM NEW
Mar 27, 2026
offering
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
<p align="justify">SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=CFtb1sDJs04jFkDk65zW
Mar 27, 2026
short_interest
FTD: ARTL — 350,631 shares ($1.1M) failed to deliver
Settlement: 20260327, Price: $3.19, FTD Value: $1,118,512.89, ARTELO BIOSCIENCES INC COM NEW
Mar 27, 2026
short_volume
Short Volume: ARTL — 55.1% short (16.8M / 30.6M)
Short: 16,832,445 | Exempt: 3,842,960 | TRF Vol: 30,557,162 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_volume
Short Volume: ARTL — 72.9% short (0.6M / 0.8M)
Short: 596,179 | Exempt: 49,327 | TRF Vol: 817,490 | Short Ratio: 72.9% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_interest
FTD: ARTL — 193,720 shares ($0.9M) failed to deliver
Settlement: 20260326, Price: $4.85, FTD Value: $939,542, ARTELO BIOSCIENCES INC COM NEW